Becker Capital Management Inc. Reduces Holdings in Hologic, Inc. $HOLX

Becker Capital Management Inc. trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,145 shares of the medical equipment provider’s stock after selling 12,756 shares during the quarter. Becker Capital Management Inc.’s holdings in Hologic were worth $4,440,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Chung Wu Investment Group LLC bought a new position in shares of Hologic in the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the period. Loomis Sayles & Co. L P bought a new stake in Hologic in the 2nd quarter worth $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Hologic in the first quarter valued at about $34,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.1%

HOLX opened at $74.83 on Thursday. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $77.32. The stock has a market cap of $16.68 billion, a PE ratio of 30.17, a PEG ratio of 2.12 and a beta of 0.70. The business has a 50 day moving average of $72.74 and a 200-day moving average of $68.11.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 earnings per share. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on HOLX. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. BTIG Research reissued a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, Evercore ISI set a $78.00 price target on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Five investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $79.29.

Insider Activity

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.